ClinConnect ClinConnect Logo
Search / Trial NCT01607125

Exploratory Study of the Effects of Vortioxetine (Lu AA21004) on Cognition and Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Subjects Remitted From Depression and in Controls

Launched by H. LUNDBECK A/S · May 25, 2012

Trial Information

Current as of June 14, 2025

Completed

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • All subjects must have:
  • a Hamilton Depression Rating Scale (HAM-D17) total score ≤ 7
  • Subjects remitted from depression must:
  • be in remission from recurrent depression having suffered from at least two previous Major Depressive Episodes (MDEs)
  • have received prescribed treatment with an antidepressant or a recognised psychotherapy for depression for a previous MDE
  • report present subjective cognitive dysfunction
  • not have been treated with antidepressants or received other psychotherapy for depression for at least six weeks prior to screening visit
  • Control group subjects must:
  • have no history of MDEs
  • have no history of MDEs in a biological parent or other first degree relative as reported by the subject
  • not report present subjective cognitive dysfunction
  • never have been treated with antidepressants or psychotherapy
  • Exclusion Criteria:
  • The subject is, in the opinion of the investigator, unlikely to comply with the clinical study protocol or is unsuitable for any other reason
  • Other inclusion and exclusion criteria may apply.

About H. Lundbeck A/S

H. Lundbeck A/S is a global pharmaceutical company dedicated to improving the quality of life for patients with brain disorders. Founded in 1915 and headquartered in Denmark, Lundbeck specializes in research, development, manufacturing, and marketing of innovative treatments for conditions such as depression, schizophrenia, and Alzheimer's disease. With a strong commitment to neuroscience, Lundbeck invests significantly in clinical trials to advance the understanding and treatment of psychiatric and neurological disorders, aiming to deliver effective solutions that address unmet medical needs worldwide.

Locations

Headington, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Email contact via H. Lundbeck A/S

Study Director

LundbeckClinicalTrials@lundbeck.com

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials